Home / Business and Economy / Laurus Labs Soars: Pharma Stock Hits Record High
Laurus Labs Soars: Pharma Stock Hits Record High
30 Oct
Summary
- Laurus Labs' stock price reached a new high of ₹2,338.90 on October 30, 2026.
- The company reported a 33% year-on-year revenue growth to ₹2,206 crore in Q2FY27.
- Foreign portfolio investors increased their stake to 30.8% in the September 2026 quarter.
Laurus Labs' stock price experienced a significant upward trend, reaching a new record high of ₹2,338.90 on October 30, 2026. This surge represents a 111% increase in its market price within the calendar year 2026. The company's strong financial performance in the September 2026 quarter (Q2FY27) is a key driver for this rally.
For Q2FY27, Laurus Labs reported a 33% year-on-year revenue growth, reaching ₹2,206 crore. The Contract Development and Manufacturing Organization (CDMO) segment saw remarkable growth of 86% year-on-year, contributing ₹875 crore. Profit after tax more than doubled to ₹441 crore from ₹195 crore in Q2FY26, bolstered by operational efficiencies and a favorable product mix.
Analysts project continued growth, with forecasts suggesting CDMO revenue could grow 3.4 times to ₹7,160 crore by FY29E. The company is also investing in new technologies and potential acquisitions in areas like Cell and Gene therapies. Meanwhile, foreign portfolio investors (FPIs) have increased their stake in Laurus Labs to 30.8% as of the September 2026 quarter.
